MIRA
INFORM REPORT
|
Report Date : |
10.09.2007 |
IDENTIFICATION DETAILS
|
Name : |
Sina Darou Laboratories Company |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1962 |
|
|
|
|
Com. Reg. No.: |
11405 |
|
|
|
|
Legal Form : |
Public Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture of pharmaceuticals, medicinal chemicals and botanical products such as Eye drops, Inhalers, Topicals, Parenterals and Syrups. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Company Details
Company Name: Sina
Darou Laboratories Company
Address:
P O
Telephone: +9821
44419521
+9821 44419522
+9821 44419523
+9821 66026630
Fax: +9821 444196603
+9821 66026603
Website: www.sina-darou.com
E-mail: sinadarou@sina-darou.com
sinadarou@hotmail.com
Company was originally started on
1962
Registration &
Legal Details
History: Sina Darou Laboratories
Company (EX-DOPAR) was established in 1962 in
engaged mostly in pharmaceutical
preparation under license of French P.O.S Company.
The company was soon expanded in
size and activities.
Current Legal Form: Public
Joint Stock Co
Registration
Address:
P O
Start Date: 1962
Registration Number: 11405
Registration Date: 1962
Capital
Currency: Iranian
Rials
Nominal capital: 39,000,000,000
Shareholders
Shareholder Names %
of Voting/Non-Voting Capital
Kharazmi Investment Co 53
Tejarat Bank 6
Iran Meli Investment Co 18
Others 16
Principals
Name: Mr. Ali Dehghan Manshadi
Position within the company: Chairman
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Ahmad Ali Ferdos
Position within the
company: Vice President
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Ahmad Karbasian
Position within the
company: Managing Director
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Ms.
Sara Zamani
Position within the
company: Secretary
Country of Birth:
Nationality: Iranian
Can fluently speak: Farsi
Company Activities
Manufacture of
pharmaceuticals, medicinal chemicals and botanical products such as Eye drops,
Inhalers, Topicals, Parenterals and Syrups
Products
NO DESCRIPTION
1 ATROPINE
0.5%
EYE DROPS
2 ATROPINE
1%
EYE DROPS
3 ARTIFICIAL
TEARS
EYE DROPS
4 BETAMTHASONE
0.1%
EYE DROPS
5 PREDNISOLONE
1%
EYE DROPS
6 PILOCARPINE
1%
EYE DROPS
7 PILOCARPINE
2%
EYE DROPS
8 PILOCARPINE 4%
EYE DROPS
9 TETRACAINE
0.5%
EYE DROPS
10 TIMOLOL
0.5%
EYE DROPS
11 SULFACETAMIDE
10%
EYE DROPS
12 SULFACETAMIDE
20%
EYE DROPS
13 PHENYLEPHRINE
5%
EYE DROPS
14 PHENYLIEPHRINE COMPOUND EYE DROPS
15 CHLORAMPHENICOL
0.5% EYE DROPS
16 NAPHAZOLINE
0.1%
EYE DROPS
17 NAPHAZOLINE +
ANTAZOLINE EYE DROPS
18 HOMATRAPINE
2%
EYE DROPS
19 IDOXURIDINE
0.1%
EYE DROPS
20 CIPROFLOXACIN
0.3%
EYE DROPS
21 BETAXSOLOL
0.5%
EYE DROPS
22 TROPICAMID
0.5%
EYE DROPS
23 TROPICAMID
1%
EYE DROPS
24 GENTAMICIN
0.3%
EYE DROPS
25 FLUOROMETHOLONE
EYE DROPS
26 CROMOLINE
2%
EYE DROPS
27 TRIFLORIDINE
1%
EYE DROPS
28 SODIUM CHLORIDE
5%
EYE DROPS
29 DEXAMTHASON
0.1%
EYE DROPS
30 SODIUM CHLORIDE
0.65%
NASAL DROP
31 PHENYLEPHRINE
0.25%
NASAL DROP
32 PHENYLEPHRINE
0.5%
NASAL DROP
33 NAPHAZOLINE
0.05%
NASAL DROP
34 CROMOLINE
13ML
NASAL
SPRAY
35 BETAMTHASONE
0.1%
OPHT.OINT
36 TETRACYCLINE 1%
OPHT.OINT
37 GENTAMYCIN
OPHT.OINT
38 VITAMINE
A
OPHT.OINT
39 HYDROCORTISONE
1%
OPHT.OINT
40 SIMPLE EYE
3.5
gr
OINTMENT
41 SODIUM CHLORIDE
5%
OPHT.OINT
42 ERYTROMICINE
0.5%
OPHT.OINT
43 ACYCLOVIR
3%
OPHT.OINT
44 TETRACYCLINE
3%
TOP.OINT
45 LIDOCAINE
2%
TOP.GEL
46 MENTHOL
SALICYLATE
TOP.OINT
47 HYDROCORTISONE 1%
15gr TOP.OINT
48 SILVER SOLFADIAZINE
TOP.CREAM
49 PEDIATRIC
GRIP SYRUP
50 PROMETHAZINE SYRUP
51 DEXTROMETHORPHAN -
P
SYRUP
52 METHOCARBAMOL
10ML AMP/5’S
53 CALCIUM GLUCONATE
10% AMP/10’S
54 AMINOPHYLINE 250
mg AMP/10’S
55 EYE BATH 250
ML
56 SALBUTAMOL 200
DOSE
AEROSOLE
Agencies:
Brevetti
Country:
Products: Pharmaceutical
Equipments
Website:
www.brevettiusa.com
Employees
Company Employs: 1025
HQ Premises
Operates from: Owned Office, Warehouse, Factory (
41000 Square Meter)
Location: Central
Business Area,
Branches
The company doesn't any
branches.
Imports
Imports : Finished
Goods
Import%: 10
Import from:
Import terms: letters of credit
Additional: balance of 90% purchased via local
market
Export
Export to: CIS
Countries,
Export term: Letters
of Credit
Export %: 15
Trading & Selling
Territory: 85 % Internationally – 15 Internationally
Type of Customer: Group
Companies
Terms of sales: letters
of credit
Vehicles: Total number of vehicles: 150
Related Companies
The subject doesn't have
any related companies.
Banks
Bank Saderat
Sanati Branche
1480, Enghelab Squre,
Financial Information
Source: Ms. Sara
Zamani
Currency: Iranian Rials -
000,000
Months Date Sales Net Gross
12 29/03/2006 216,157 64,197 90,402
12 29/03/2005 163,370 40,978 62,008
12 29/03/2004 136,846 44,581 50,829
BALANCE SHEET
Source: Financial
Estimates on 29/03/2006
Currency: Iranian
Rials
Note: Figures in 000,000
NEW WORTH
74,538
Trade Creditor
78,000
Total Liabilities 105,774
Trade Debtors
89,000
Total Assets 169,312
Payments
Subject's payments reported to be: NO COMPLAINTS
Solicitor: Rahbin Service
Co
Auditors: Mr.Hossein
Sheikh Safli
interview &
reporter comments
Name/Title: Ms. Sara
Zamani - Secretary
In the interview
conducted With Ms. Sara
Zamani She
declined bank account numbers citing the grounds of
company confidentiality
Conclusion
Local Reputation:
The company being investigated is considered by local reporters to be a Medium
TRADE Risk and
Owner/Shareholders Comments: Some of owners involved in the running of the
business
Age of Business: Old Business
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)